A detailed history of Ossiam transactions in Moderna, Inc. stock. As of the latest transaction made, Ossiam holds 13,775 shares of MRNA stock, worth $507,608. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,775
Previous 19,791 30.4%
Holding current value
$507,608
Previous $2.35 Million 60.85%
% of portfolio
0.02%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$63.64 - $125.14 $382,858 - $752,842
-6,016 Reduced 30.4%
13,775 $920,000
Q2 2024

Aug 13, 2024

BUY
$101.21 - $166.61 $100,096 - $164,777
989 Added 5.26%
19,791 $2.35 Million
Q1 2024

May 13, 2024

BUY
$85.37 - $115.44 $439,228 - $593,938
5,145 Added 37.67%
18,802 $2 Million
Q4 2023

Feb 13, 2024

BUY
$69.51 - $104.43 $3,823 - $5,743
55 Added 0.4%
13,657 $1.36 Million
Q3 2023

Nov 14, 2023

BUY
$96.41 - $126.61 $771 - $1,012
8 Added 0.06%
13,602 $1.4 Million
Q2 2023

Aug 11, 2023

SELL
$118.5 - $160.53 $159,619 - $216,233
-1,347 Reduced 9.02%
13,594 $1.65 Million
Q1 2023

May 12, 2023

SELL
$135.66 - $197.02 $349,867 - $508,114
-2,579 Reduced 14.72%
14,941 $2.29 Million
Q4 2022

Feb 13, 2023

BUY
$118.38 - $210.04 $1.48 Million - $2.62 Million
12,486 Added 248.03%
17,520 $3.15 Million
Q3 2022

Nov 14, 2022

BUY
$118.07 - $194.18 $213,824 - $351,659
1,811 Added 56.19%
5,034 $595,000
Q2 2022

Aug 12, 2022

BUY
$117.13 - $176.59 $377,509 - $569,149
3,223 New
3,223 $460,000
Q1 2022

May 13, 2022

SELL
$126.46 - $235.05 $97,247 - $180,753
-769 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$225.82 - $368.51 $3.74 Million - $6.1 Million
-16,566 Reduced 95.56%
769 $195,000
Q3 2021

Nov 12, 2021

BUY
$221.9 - $484.47 $3.85 Million - $8.4 Million
17,335 New
17,335 $6.67 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Ossiam Portfolio

Follow Ossiam and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ossiam, based on Form 13F filings with the SEC.

News

Stay updated on Ossiam with notifications on news.